Lesson
Recognize the Influenza Decision State
Influenza A and B create an acute respiratory syndrome whose urgency depends on host, severity, trajectory, setting, and competing diagnoses rather than a test result alone.
- Influenza A and B
- High-risk host
- Hospitalization
- Bacterial complication
- Vaccination
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Recognize the syndrome
Abrupt fever, cough, myalgia, headache, fatigue, chills, and sore throat can support influenza, but presentation varies. COVID-19, bacterial pneumonia, and other respiratory pathogens can coexist or resemble it.
Treat priority patients now
Hospitalized patients, patients with severe or progressive illness, and patients at high risk for complications should receive empiric treatment as soon as possible. Do not wait for laboratory confirmation when influenza is suspected.
Detect deterioration
Dyspnea, hypoxemia, dehydration, hypotension, altered mental status, chest pain, or a biphasic new fever deserves urgent reassessment. Influenza antivirals do not treat bacterial pneumonia or other complications.
Preserve prevention
Antiviral treatment or prophylaxis does not replace seasonal vaccination, source control, respiratory hygiene, or outbreak planning. Confirm which vaccine product was used because live intranasal vaccine has antiviral timing concerns.
Quick check
Lesson
Interrupt Viral Release or Transcription
Recommended influenza antivirals act at two distinct viral systems: neuraminidase-mediated release and polymerase-acidic endonuclease-mediated transcription.
- Sialic acid
- Neuraminidase
- Cap snatching
- PA endonuclease
- Resistance substitution
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Block progeny release
Oseltamivir carboxylate, zanamivir, and peramivir inhibit influenza A and B neuraminidase. Blocking cleavage of terminal sialic acid limits release and spread of newly formed virions.
Block cap snatching
Active baloxavir inhibits the polymerase acidic endonuclease that cleaves capped host RNA fragments used to prime viral messenger RNA transcription. This target acts before virion assembly and release.
Retire the adamantanes
Amantadine and rimantadine inhibit the M2 ion channel of influenza A but are not recommended in the United States because circulating seasonal viruses have widespread resistance.
Place resistance in context
Neuraminidase substitutions and PA substitutions can reduce susceptibility. Persistent illness still requires a broader audit of diagnosis, timing, absorption, delivery, host, compartment, and bacterial complication before resistance is assigned.
Quick check
Lesson
Match Drug to Patient and Setting
Benefit is greatest when treatment begins early, but the 48-hour principle does not exclude later treatment in hospitalized, severe, progressive, or high-risk disease.
- Early treatment
- Hospitalized oseltamivir
- Uncomplicated outpatient
- Route fit
- Baloxavir boundary
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Use time correctly
Treat eligible uncomplicated outpatients as early as possible, ideally within two days. Do not turn 48 hours into a universal cutoff for hospitalized, severe, progressive, or high-risk patients.
Protect hospitalized selection
CDC recommends oral or enterically administered oseltamivir as soon as possible for hospitalized suspected or confirmed influenza. Inhaled zanamivir, peramivir, and baloxavir are not routinely recommended there because clinical-benefit evidence is insufficient.
Compare outpatient options
Oseltamivir, zanamivir, peramivir, and baloxavir can treat eligible uncomplicated outpatients within two days. Age, weight, airway disease, swallowing, inspiratory flow, IV need, renal function, pregnancy, lactation, immune status, interactions, and access decide fit.
Respect baloxavir limits
CDC does not recommend baloxavir monotherapy in pregnancy, breastfeeding, immunocompromise, hospitalization, complicated illness, or progressive illness. Current approval begins at age 5 for eligible uncomplicated disease.
Quick check
Lesson
Activate the Oseltamivir Prodrug
Oseltamivir phosphate is an orally absorbed ester prodrug converted predominantly by hepatic esterases to oseltamivir carboxylate, an influenza neuraminidase inhibitor eliminated in urine.
- Ester prodrug
- Hepatic esterase
- Active carboxylate
- Neuraminidase
- Renal secretion
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Read the prodrug scaffold
The ethyl ester improves oral delivery. Hepatic esterases convert absorbed oseltamivir to the polar carboxylate, and at least three quarters of an oral dose reaches systemic circulation as active metabolite.
Inhibit neuraminidase
Oseltamivir carboxylate limits release of influenza A and B progeny virions. Early use restricts new spread but does not instantly restore respiratory epithelium already damaged by infection.
Follow elimination
The active metabolite is not further metabolized and is eliminated unchanged in urine through filtration and tubular secretion. Falling renal function raises exposure and requires indication-specific adjustment.
Avoid an invented CYP list
Neither oseltamivir nor its active metabolite is a clinically meaningful CYP substrate or inhibitor. Vaccine timing, renal function, formulation ingredients, and exact documented interactions deserve more attention than broad CYP warnings.
Quick check
Lesson
Calculate Oseltamivir Exposure
Treatment, prophylaxis, age, weight, concentration, renal function, dialysis, formulation, food, and storage must be verified independently.
- 75 mg twice daily
- Pediatric weight band
- 6 mg per mL
- Renal adjustment
- Storage interval
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Separate treatment from prophylaxis
Standard adult uncomplicated-influenza treatment is 75 mg twice daily for five days. Prophylaxis commonly uses 75 mg once daily, with duration set by exposure or outbreak context and current guidance.
Use current pediatric dosing
Label treatment begins at 2 weeks with 3 mg/kg twice daily before age 1, then weight bands from age 1 through 12. CDC also recommends selected off-label treatment below 14 days and prophylaxis from 3 months through 1 year.
Calculate suspension volume
The constituted commercial suspension is 6 mg/mL. A 45 mg dose requires 7.5 mL. Shake well, use a milliliter-calibrated oral device, and make sure the caregiver can deliver the full course.
Adjust and store precisely
Adult treatment falls to 30 mg twice daily at creatinine clearance above 30 through 60 mL/min and 30 mg once daily above 10 through 30 mL/min, with dialysis-specific regimens. Commercial suspension is used within 17 refrigerated days or 10 room-temperature days.
Quick check
Lesson
Monitor the Host and Formulation
Oseltamivir safety joins common gastrointestinal effects to rare immune reactions, neurologic symptoms of uncertain attribution, bacterial complications, formulation sorbitol, pregnancy, and lactation.
- Nausea and vomiting
- Skin reaction
- Neuropsychiatric event
- Sorbitol
- Pregnancy
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Improve gastrointestinal tolerance
Nausea and vomiting commonly occur early and may improve when oseltamivir is taken with food. Protect hydration, determine whether doses were retained, and reassess severe or persistent symptoms.
Stop serious reactions
Anaphylaxis, angioedema, and severe skin or mucosal reactions require immediate withdrawal and appropriate treatment. Do not continue through a progressive immune syndrome.
Monitor behavior safely
Influenza can cause delirium, hallucinations, seizures, encephalopathy, and abnormal behavior. Uncommon events have also been reported during therapy. Protect the patient from injury and evaluate infection and treatment together rather than assuming causality.
Protect special populations
A 75 mg suspension dose delivers 2 grams of sorbitol and can harm a patient with hereditary fructose intolerance. CDC prefers oseltamivir in pregnancy; human milk levels are low, and current narrative evidence replaces obsolete pregnancy letters.
Quick check
Lesson
Verify the Zanamivir Device and Airway
Zanamivir is an inhaled neuraminidase inhibitor whose efficacy and safety depend on the Diskhaler, inspiratory delivery, airway health, milk-protein allergy, and live-vaccine timing.
- Diskhaler
- Two inhalations
- Bronchospasm
- Milk protein
- LAIV timing
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Build the labeled dose
Treatment from age 7 is 10 mg twice daily for five days. Each 10 mg dose requires two separate 5 mg blister inhalations. When possible, give two first-day doses at least two hours apart, then about 12 hours apart.
Demonstrate the device
Load the Rotadisk, pierce only when ready, exhale away from the device, inhale through the mouthpiece, and confirm both blisters. Never nebulize or mechanically transfer the powder.
Protect vulnerable airways
Zanamivir is not recommended with asthma or COPD. Serious and fatal bronchospasm has occurred. Stop for wheeze or declining respiratory function and provide immediate respiratory treatment when needed.
Check allergy and vaccine timing
The lactose excipient contains milk proteins and is contraindicated in true milk-protein allergy. Keep intranasal live attenuated vaccine at least two weeks before or 48 hours after zanamivir unless medically indicated.
Quick check
Lesson
Build the Peramivir Infusion
Peramivir is a renally eliminated intravenous neuraminidase inhibitor delivered as one diluted infusion for eligible acute uncomplicated influenza.
- Single infusion
- 12 mg per kg
- 600 mg maximum
- Renal reduction
- Dilution
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Define the clinical role
Peramivir is approved from age 6 months for acute uncomplicated influenza within two days. It is not used for prophylaxis, and routine monotherapy is not recommended for hospitalized serious influenza.
Calculate age and weight
Adults and adolescents at least 13 years receive 600 mg once. Patients 6 months through 12 years receive 12 mg/kg once, capped at 600 mg. A 30 kg child receives 360 mg before renal adjustment.
Protect renal exposure
The adult single dose falls to 200 mg at creatinine clearance 30 to 49 mL/min and 100 mg at 10 to 29 mL/min. Pediatric proportional reductions apply from age 2, while data are insufficient below age 2 with clearance below 50.
Prepare and monitor
Dilute the 10 mg/mL vial to a final concentration of 1 to 6 mg/mL in a compatible diluent and infuse over 15 to 30 minutes. Do not mix or co-infuse other intravenous drugs. Stop for anaphylaxis or serious skin reaction.
Quick check
Lesson
Block Viral Transcription with Baloxavir
Baloxavir marboxil is a lipophilic ester prodrug hydrolyzed to active baloxavir, which inhibits the influenza polymerase acidic cap-dependent endonuclease.
- Marboxil prodrug
- Active baloxavir
- PA endonuclease
- Single dose
- Weight band
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Activate the prodrug
Hydrolysis converts baloxavir marboxil to baloxavir. The prodrug architecture supports oral delivery while the active species inhibits an influenza-specific polymerase function.
Interrupt transcription
Baloxavir blocks PA endonuclease and prevents cap snatching required for viral messenger RNA transcription. This mechanism is distinct from neuraminidase inhibition.
Use the current label
Treatment and post-exposure prophylaxis begin at age 5. Tablets use 40 mg once from 20 to less than 80 kg and 80 mg once at 80 kg or more. Current RxPrep age-12 language is outdated.
Calculate the pediatric liquid
Bottle suspension is 2 mg/mL. Below 20 kg, use 2 mg/kg. A 14 kg child requires 28 mg, which equals 14 mL. Confirm the presentation because packets and bottles have different delivery rules.
Quick check
Lesson
Protect the Baloxavir Single Dose
One-dose convenience requires exact cation separation, formulation preparation, age, setting, allergy, resistance, pregnancy, lactation, and immune-status verification.
- Polyvalent cation
- Ten-hour stability
- Hypersensitivity
- Age 5 boundary
- Population limit
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Avoid chelation
Do not administer with dairy products, calcium-fortified beverages, cation-containing antacids or laxatives, or oral calcium, iron, magnesium, selenium, or zinc supplements. Cations can reduce baloxavir exposure.
Prepare the bottle correctly
Reconstitute to 2 mg/mL, gently swirl rather than shake, label the time, and administer within 10 hours because the product lacks preservative. Use an oral or enteral syringe and the required tube flush.
Recognize serious reactions
Anaphylaxis, angioedema, urticaria, erythema multiforme, severe gastrointestinal bleeding syndromes, and abnormal behavior have been reported. Stop and evaluate serious immune findings.
Respect evidence limits
Do not use below age 5 because treatment-emergent resistance was more frequent. CDC does not recommend monotherapy in pregnancy, breastfeeding, immunocompromise, hospitalization, complicated disease, or progressive disease.
Quick check
Lesson
Close the Influenza Treatment Loop
A safe influenza plan connects syndrome, host, severity, setting, onset, drug target, route, dose, organ function, vaccine timing, response, complication, resistance, and ownership.
- Treatment
- Prophylaxis
- LAIV
- Deterioration
- Public health
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Separate treatment and prevention
A symptomatic patient needs a treatment decision. Post-exposure prophylaxis requires exposure timing, host risk, age, vaccine status, outbreak context, product indication, and a distinct regimen.
Coordinate live vaccine timing
Antivirals can suppress replication of intranasal live attenuated vaccine. Verify the product and dates and follow agent-specific spacing. Inactivated vaccine is not governed by the same live-virus mechanism.
Audit worsening illness
Reassess oxygenation, hemodynamics, bacterial pneumonia, COVID-19, adherence, absorption, device or infusion delivery, renal dose, immune status, and resistance. Do not automatically repeat a single dose.
Use current evidence
CDC recommendations change with circulating susceptibility and evidence. This module supports verification but does not replace patient-specific diagnosis, current seasonal guidance, labeling, local policy, or qualified prescribing.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 192 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.